Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
Saks Global Enterprises Seeks $1 Billion Loan Amid Possible Chapter 11 Bankruptcy Filing 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
EMERYVILLE, Calif., March 15, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will provide a corporate overview at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22, 2017, in New York, NY.
| Zogenix Presentation Details | |
| Date: | Wednesday, March 22, 2017 |
| Time: | 2:10 pm Eastern Time / 11:10 am Pacific Time |
| Location: | New York, NY - Westin New York Grand Central Hotel |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
